• Bryostatin-1 Study Does Not Meet Primary Endpoint americanpharmaceuticalreview
    September 10, 2019
    Neurotrope announced its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance on the primary endpoint...
PharmaSources Customer Service